Find XO: Biod Selected in a Market Where 95% of AI Drug Pilots Fail (venturesquare.net)

- Biod was selected for the Ministry of SMEs and Startups' 'Super Gap 1000+' program, securing up to 600 million KRW in funding. - It is welcome news for early-stage bio teams because they can continue research without giving up equity. - By deciding which tasks in drug development to improve and which experiments to finish before the funding runs out, the content to show to the next investor becomes much clearer.